(Q35780357)

10 August 2017

1 reference

title

Review of health economics modelling in rheumatoid arthritis (English)

1 reference

10 August 2017

1 reference

1

Paul Emery

0 references

publication date

1 January 2004

1 reference

10 August 2017

1 reference

10 August 2017

volume

22

1 reference

10 August 2017

issue

2 Suppl 1

1 reference

10 August 2017

page(s)

55-69

1 reference

https://scigraph.springernature.com/pub.10.2165/00019053-200422001-00006

10 August 2017

exact match

0 references

cites work

Pharmacoeconomics of drug therapy for rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.2165%2F00019053-200422001-00006

Evaluation of costs in rheumatic diseases: a literature review

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00019053-200422001-00006

Disease-modifying anti-rheumatic drug therapy. An expensive therapy despite inexpensive drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00019053-200422001-00006

The total costs of drug therapy for rheumatoid arthritis. A model based on costs of drug, monitoring, and toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00019053-200422001-00006

Willingness to pay in arthritis: a Danish contribution.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00019053-200422001-00006

A cost-effectiveness analysis of treatment options for patients with methotrexate-resistant rheumatoid arthritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00019053-200422001-00006

A clinical and economic review of disease-modifying antirheumatic drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00019053-200422001-00006

An economic model for determining the costs and consequences of using various treatment alternatives for the management of arthritis in Canada

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00019053-200422001-00006

Indirect medical costs in early rheumatoid arthritis: composition of and changes in indirect costs within the first three years of disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00019053-200422001-00006

Treatment strategy, disease activity, and outcome in four cohorts of patients with early rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00019053-200422001-00006

Evidence from clinical trials and long-term observational studies that disease-modifying anti-rheumatic drugs slow radiographic progression in rheumatoid arthritis: updating a 1983 review.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00019053-200422001-00006

Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00019053-200422001-00006

Adalimumab (a fully human anti-tumour necrosis factor alpha monoclonal antibody) in the treatment of active rheumatoid arthritis: the initial results of five trials

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00019053-200422001-00006

Long term anti-tumour necrosis factor alpha monotherapy in rheumatoid arthritis: effect on radiological course and prognostic value of markers of cartilage turnover and endothelial activation.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00019053-200422001-00006

A cost-cost study comparing etanercept with infliximab in rheumatoid arthritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00019053-200422001-00006

An assessment of the annual and long-term direct costs of rheumatoid arthritis: the impact of poor function and functional decline

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00019053-200422001-00006

Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00019053-200422001-00006

Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis. Comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumati

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00019053-200422001-00006

Cost evaluation of novel therapeutics in rheumatoid arthritis (CENTRA): a decision analysis model

21 January 2018

1 reference

12 December 2020

Direct cost of rheumatoid arthritis during the first six years: a cost-of-illness study.

1 reference

12 December 2020

Cost-effectiveness and cost-utility of combination therapy in early rheumatoid arthritis: randomized comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone. COBRA Trial Group. Combinatietherapie Bij

1 reference

12 December 2020

A cost effectiveness analysis of treatment options for methotrexate-naive rheumatoid arthritis

1 reference

12 December 2020

Modeling the lifetime costs of rheumatoid arthritis.

1 reference

12 December 2020

The total cost of drug therapy for rheumatoid arthritis: comment on the article by Prashker and Meenan

1 reference

12 December 2020

Predicting the short term direct medical costs incurred by patients with rheumatoid arthritis

1 reference

12 December 2020

Report of the OMERACT task force on economic evaluation. Outcome Measures in Rheumatology

1 reference

12 December 2020

Long-term morbidity, mortality, and economics of rheumatoid arthritis

1 reference

12 December 2020

A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis

1 reference

12 December 2020

The cost effectiveness of auranofin: results of a randomized clinical trial

1 reference

12 December 2020

The FDA and regulation of cost-effectiveness claims

1 reference

12 December 2020

Radiographic damage in rheumatoid arthritis correlates with functional disability but not direct medical costs

1 reference

12 December 2020

The impact of pharmaco-economic considerations on the utilization of novel anti-rheumatic therapies

1 reference

12 December 2020

Impact of leflunomide versus biologic agents on the costs of care for rheumatoid arthritis in a managed care population.

1 reference

12 December 2020

Evidence supporting the benefit of early intervention in rheumatoid arthritis

1 reference

12 December 2020

Economic consequences of the progression of rheumatoid arthritis in Sweden

1 reference

12 December 2020

Assessing cost-effectiveness analyses in rheumatoid arthritis and osteoarthritis

1 reference

12 December 2020

10.2165/00019053-200422001-00006

Identifiers

DOI

0 references

Dimensions Publication ID

1050906217

0 references

1 reference